MitoRx’s pipeline is built around our lead asset MTRX31

Pipeline

A first-in-class small molecule being developed as a monotherapy for high-risk obesity by restoring healthy mitochondrial metabolism, with potential to be used as a first-line therapy in certain patient populations.

Preclinical data for MTRX31 has shown superior magnitude, quality and durability of weight loss compared with tirzepatide in an industry-standard preclinical model of obesity. MTRX31-driven weight-loss does not involve lean mass loss.

Currently being advanced for subcutaneous administration, MitoRx Therapeutics is also developing an orally optimized derivative of MTRX31.

Metabolically Unhealthy Obesity (subcut)

MTRX31 achieved preclinical PoC DIO model

Better quality, quantity and durability of weight loss than standard-of-care

Past: Pre-clinical
Next: Clinical candidate

Metabolically Unhealthy Obesity (oral)

Orally optimized derivative of MTRX31

Past: Hit-to-Lead
Next: Lead optimization